Trending...
- EntryLevelActing.LA Website and Interview Published in Prep for Sat. HollywoodActorJobs.com Workshop - 143
- Class is in session: Black Beauty Block Party returns to Los Angeles for fourth annual festival - 120
- Governor Newsom signs legislation enacting long-recommended changes to improve TK-12 school governance in California - 118
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to virtually participate in the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 5:15 p.m. ET.
A live and archived webcast for this event will be available in the Investors section of the Glaukos website at http://investors.glaukos.com.
About Glaukos
Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent®, its first MIGS device, in the United States in 2012, its next-generation iStent inject® device in the United States in 2018 and most recently, its iStent injectW device in the United States in 2020. In corneal health, Glaukos' proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.
More on The Californer
Contacts
Chris Lewis
Sr. Director, Investor Relations & Corporate Strategy & Development
(949) 481-0510
clewis@glaukos.com
A live and archived webcast for this event will be available in the Investors section of the Glaukos website at http://investors.glaukos.com.
About Glaukos
Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent®, its first MIGS device, in the United States in 2012, its next-generation iStent inject® device in the United States in 2018 and most recently, its iStent injectW device in the United States in 2020. In corneal health, Glaukos' proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.
More on The Californer
- La Jolla Montessori School Awarded "Best Preschool" in La Jolla, California
- Beverage Companies Are Modernizing Distributor Agreement Management in 2026
- California: MORE HOUSING, FASTER: Governor Newsom signs historic housing affordability reforms
- Apex Lane Logistics Expands Carrier Network, Strengthening Freight Capacity Across the Western U.S
- Studica Robotics Supports Robotics Training Camp for WorldSkills Shanghai 2026
Contacts
Chris Lewis
Sr. Director, Investor Relations & Corporate Strategy & Development
(949) 481-0510
clewis@glaukos.com
Filed Under: Business
0 Comments
Latest on The Californer
- Governor Newsom extends business incentive program, bolstering California's nation-leading job creation
- California: As Trump cedes global clean car race to China, Governor Newsom fights back with instant ZEV rebates for first-time buyers
- Global Chief Happiness Officer Edwin Edebiri Launches The CHO Collective®: A Global Movement Dedicated to Mastering Happiness as a Learnable Skill
- Qscription Technologies Appoints Radiology Industry Veteran Elliot Silverman to Advisory Board
- How Restaurants Are Staying Ahead of Fair Workweek Laws in 2026
- RadioMobile Deploys IQ Fire Station Alerting System at Pleasant Hill Goshen Fire & Rescue
- Desna Therapeutics Receives SBIR Grant for Novel Immune Reprogramming Therapy in Type 1 Diabetes
- Search Is Broken. Curated Discovery Is the Future
- 20 Ways to Save Money Running a Van
- How Fortress Law Group Turned a DUI Arrest in Ohio Into a Full Acquittal at Trial
- Breaking the Silence: Tour Sparks National Conversation on Men's Mental Health and Domestic Abuse
- Mr. Hospital Bed Helps Home Care Buyers Find the Right Hospital Bed
- Healthcare Organizations Shift Toward Integrated Growth Strategies as Leadership, Operations, and Te
- The Convergence of Healthcare, Construction, and Managed Services Organizations
- FatWealth - How FatWealth.com's Asynchronous Training Gives Fitness Coaches Their Life Back
- Salestrics Momentum Accelerates Following Fundraising Announcement and Orbit! Launch
- Salestrics Announces $1.5 Million SAFE Financing Round to Accelerate Growth
- LA Lemon Lawyer Provides Insight Into How Much Your Toyota Lemon Law Case May Worth in Los Angeles
- Hutchinson Joins Exclusive List of Top Authors with Twenty Plus Books in the Nation's Libraries
- Genni AI Launches AI Shopping Agent Built for Shopify Stores